Research Article Highlights Advantageous Use Of AlbuVoid™ in Clinical Proteomics

MONMOUTH JUNCTION, NJ, March 1, 2019 -- Biotech Support Group reports on anew research report

which highlights the simplicity and efficiency of theirAlbumin depletion sample preparation

technology as an enrichment step forclinical research of human serum using LC-MS proteomic

analysis. The citationis:

Vialaret, Jerome & Kadi, Sarah & Tiers, Laurent & OFlynn, Robin & Lehmann, Sylvain & Hirtz,

Christophe. (2018). Albumindepletion of human serum to improve quantitative clinical proteomics.

CurrentTopics in Peptide & Protein Research 19. 53-62.             

http://www.researchtrends.net/tia/abstract.asp?in=0&vn=19&tid=26&aid=6192&pub=2018&type=3

Proteins are essential for biomarker and disease discoverythough the most abundant proteins

often provide very limited clinicallyrelevant data, as can be the case for albumin or immunoglobulins.

In this work,the investigators focused on depleting albumin from human serum samples usingan

albumin depletion and low abundance protein enrichment kit – AlbuVoid™,which enabled the

detection of several low-abundance proteins. By employing anoptimized protocol, enriched proteins

known as biomarkers for various diseaseswere identified. The article states “Protein capture was

performed using AlbuVoid™ Kit on serumsamples… For the LCMS analysis, elution was made directly

on the beads withdenaturant solution (30 μL of 8 M urea / 20 mM DTT / 100 mM Tris pH 8.5) before

tryptic digestion. In comparison, methods using antibodies needed at leastone-half day more. The

albumin depletion method allowed to save precious time.”. The authorsconcluded that the AlbuVoid

depletion method proved to be faster and morecost-effective than antibody based methods, and

could be helpful for biomarkerenrichment and detection in medical research.

“Throughout our product and methods development efforts, we have been especially focused on

overcoming the challenges of clinical proteomics. So I am are very pleased tosee that AlbuVoid™

was advantageously used for this purpose. Because we use aporous silica bead surface chemistry,

the strong denaturing conditions studiedhere as the bead eluent. can provide a seamless workflow

to FASP type digests.Consequently, the versatility of digest conditions, either FASP or on-bead

digest - what we call BASP™, can offer many workflow and unique digestefficiency options.

Collectively we continue to find new benefits for clinicaldiscovery and targeted proteomics.” states

Swapan Roy, Ph.D., President and Founderof Biotech Support Group.

For more information on AlbuVoid™, go to:

http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

For more information on the BSG complete line of Albumin & IgG Removal products, visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=451